Mobility Global Inc. Common Stock vs Medpace Holdings Inc — how do they compare? Mobility Global Inc. Common Stock trades at $17.85 (market cap $5.71B), while Medpace Holdings Inc trades at $616.98 (market cap $17.21B). The key difference: Medpace Holdings Inc is far larger — about 3× Mobility Global Inc. Common Stock's market cap, and Mobility Global Inc. Common Stock pays a 1.35% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mobility Global Inc. Common Stock for 0 Days and Medpace Holdings Inc for 14 Days on average.
| MBGL | MEDP | |
|---|---|---|
Market Cap | $5.71B | $17.21B |
Volume | 3,135,791 | 311,245 |
Sector | Technology | Health |
52-Week High | $22.26 | $630.19 |
52-Week Low | $17.15 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $7.53B | $16.83B |
Dividend Yield | 1.35% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $609.89, down 1.64% today, with a bullish technical signal and strong support near $606. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue grew to $2.53B in 2025, with a net income margin of 17.67%. Recent news highlights CEO stock sales and institutional position adjustments.
Outlook remains positive with a consensus price target of $620.44, offering modest upside. Key risks include high valuation multiples and insider selling. Earnings growth and sector demand are primary catalysts, but investor caution is warranted given elevated P/E and P/B ratios.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mobility Global Inc. provides automotive data and analytics across the vehicle lifecycle, operating brands including CARFAX, automotiveMastermind, Polk Automotive Solutions, and Market Scan for automakers, dealers, and consumers.
Read more on MBGL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →